Login
Navigate Fool.com
Will VNDA beat
the market?
Community Rating: 1 Star: Ominous

13.58 -0.27 (-1.95%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.72
Previous Close $13.85
Daily Range $13.31 - $14.25
52-Week Range $4.41 - $19.25
Market Cap $455.0M
P/E Ratio -20.67
Dividend (Yield) $0.00 (0.0%)
Volume 904,063
Average Daily Volume 1,314,609
Current FY EPS -$1.29

How do you think VNDA
will perform against the market?

Top VNDA Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted August 4, 2011

If you're looking around for falling knives to catch, may I recommend Vanda? The stock can never get any liftoff because royalties from their single product Fanapt have plateaued under 1M/quarter, and … More

0 Replies Reply Report this Post
 

hlacheen (< 20)
Submitted February 14, 2007

Utter garbage.... like most pharmaceutical companies with huge losses and horrible balance sheets.

1 Replies Reply Report this Post

News & Commentary Rss Feed

Does Mannkind Offer a Good Risk to Reward Ratio?

MannKind Corp.'s regulatory review for Afrezza is close at hand. Does the stock offer a favorable risk to reward profile?

3 Stocks Near 52-Week Highs Worth Selling

Are these three stocks sells or belles? You be the judge!

Vanda Pharmaceuticals' Q4 Loss Widens on Higher Expenses

Vanda Pharmaceuticals reduced R&D expenses by 41%, but a tripling in SG&A expenses combined with modest Fanapt growth caused its loss to widen by 20%.

3 Horrendous Health-Care Stocks This Week

Which health-care stocks had as lousy of a week as Broncos fans? Here are 3 big losers from the past few days.

Why Vanda Pharmaceuticals Won Big Today

How an FDA approval for this sleep/wake disorder drug made Vanda Pharmaceuticals today's big biotech winner.

A Short-Lived FDA Approval Pop

Vanda Pharmaceuticals gained FDA approval for Hetlioz, but investors appear worried about how the drug will sell. Arena Pharmaceuticals and VIVUS are good examples of other biotechs that haven't lived up to their expectations.

Will the FDA Approve Vanda's Hetlioz?

Vanda Pharmaceuticals faces the FDA firing squad. Will it have similar fare to Sarepta Therapeutics and InterMune?

Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential

Following Smart Money: Baker Brothers LLC Investments in 2013 and Beyond, Part 2

3 FDA Actions to Focus on in January

January may be a slower month for the Food and Drug Administration, but these three FDA actions have very important implications for investors.

See More VNDA News...

Sector

Healthcare

Industry

Drugs

Vanda Pharmaceuticals, Inc. (VNDA) Description

A biopharmaceutical company focused on the development and commercialization of clinical-stage drug candidates, with exclusive worldwide commercial rights to three product candidates in clinical development for various central nervous system disorders. Website: http://www.vandapharmaceuticals.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks